Artoflex300 mg

Artoflex 300 mg is indicated in- The relief of sign and symptoms of osteoarthritis. Indicated in rheumatoidal disorders such as osseous rheumatism, ankylosing spondilitis, juvenile arthritis, muscular rheumatism, degenerative joint diseases Acute symptomatic treatment of painful menstruation (primary dysmenorrhoea) ... Read moreArtoflex 300 mg is indicated in- The relief of sign and symptoms of osteoarthritis. Indicated in rheumatoidal disorders such as osseous rheumatism, ankylosing spondilitis, juvenile arthritis, muscular rheumatism, degenerative joint diseases Acute symptomatic treatment of painful menstruation (primary dysmenorrhoea) Common headache and fever Symptomatic treatment of mild to moderate pain, such as muscle pain, headache and dental pain As an adjuvant with common cold and influenza associated with headache.

Drugs for Osteoarthritis, Drugs used for Rheumatoid Arthritis, Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Like common NSAIDs, Artoflex 300 mg is an active enantiomer of ibuprofen that suppresses the prostanoid synthesis in the inflammatory cells via inhibition of the COX-2 isoform of the arachidonic acid COX. Attenuating the synthesis of prostaglandins and thromboxanes gives the drug three major therapeutic actions. Anti-inflammatory action comes from decreased prostaglandin E2 and prostacyclin leading to decreased vasodilation and oedema that enhances vascular permeability and activity of inflammatory mediators. Decreased prostaglandin levels in the hypothalamus confers the antipyretic effect of the drug. Analgesic effect stems from decreased prostaglandin levels that sensitize the nociceptors to inflammatory mediators at sites of pain and enhance transmission from afferent pain fibers at the spinal cord

The recommended dosage of Artoflex 300 mg is 600 to 900 mg/day, at 2-3 divided doses. Maximum single dose is 400 mg. The dosage can be raised temporarily up to 1200 mg/day in patients with acute disorders or exacerbations.

The dosage must be adjusted to the seriousness of the syndrome and the complaints of the patient. During chronic pain, the dosage must be adapted to the lowest effective dose.The recommended dosage: 600-900 mg Artoflex 300 mg per day, at 2-3 divided doses. The dosage can be raised temporarily up to 1200 mg Artoflex 300 mg per day in patients with acute disorders or exacerbations. The maximum daily dose is 1200 mg.At dysmenorrhea: A dosage of 600 up to 900 mg Artoflex 300 mg per day, at a divided dose.

The reported drug interactions of Artoflex 300 mg are similar to that of racemic mixture of ibuprofen. Drug interactions is noticed with simultaneous use of anticoagulant, hydantoine and sulfonamide, ticlopidine, lithium, other NSAID's, ACE inhibitors, beta blockers, cyclosporine, tacrolimus, corticosteroids, digoxin, methotrexate, pentoxyfiline, phenytoine, probenecid, sulfinpyrazon, sulfonylurea, thiazide and thiazide type diuretics, and zidovudine.

Artoflex 300 mg is contraindicated in patients with previous history of hypersensitivity to Artoflex 300 mg, or another NSAID, or any other component of the product. Patients, who experience attack of asthma, arouse bronchospasm, acute rhinitis, urticaria or edema after use of similar drugs (e.g. aspirin or other NSAID's). It is also contraindicated in patients with active or suspected hemorrhage, Crohn's disease or ulcerative colitis, patients with serious heart diseases, kidney function impairment (GFR <30ml/min), and liver function impairment.

Clinical experience has shown that adverse effects of Artoflex 300 mg are similar to those of racemic ibuprofen. Common side-effects are dyspepsia, diarrhea, fatigue, and headache, nausea, vomiting, abdominal pain, hypersensitivity reactions - bleeding, ulcer.

Pregnancy: no clinical data on exposed pregnancies are available.Lactation: Ibuprofen is slightly excreted in human milk. Breast-feeding is possible with Artoflex 300 mg if dosage is low and the treatment period is short.

Artoflex 300 mg should be used with particular caution in patients with bronchial asthma or other chronic diseases of the pulmonary tract as well as in persons prone to allergy. The drug should be used in patients with hepatic, renal or cardiac insufficiency and with hypertension not responding to any treatment. Consultation with a doctor is recommended for patients with systemic lupus or with other autoimmunological disease before beginning therapy using the drug. Artoflex 300 mg should be used with extreme cautions in active and suspected hemorrhagic conditions such as gastro-duodenal ulcers, ulcerative colitis, Crohn's disease, alcoholism. Allergic reactions to the drug may appear even for the first-time user and in such case, it should immediately be stopped.

Artoflex 300 mg has low acute toxicities. Symptoms of toxicity occur at doses between 80 and 100 mg/kg body weight. Mild symptoms are abdominal pain, nausea, vomiting, lethargy, headache, tinnitus and ataxia. Moderate to serious symptoms, such as flatulence, hypotension, hypothermia, metabolic acidosis, reduced kidney function, coma, and apnoea. The treatment must be symptomatic: there is no specific antidote. In case of large quantities of Artoflex 300 mg, activated charcoal should be administered. Vomiting can be induced only when life-threatening quantities of the substance ingested and the procedure can be carried out within 60 minutes after ingestion. Dialysis and hemodialysis are of little value as Artoflex 300 mg binds strongly to plasma protein.

Do not store above 30°C. Keep away from light and out of the reach of children

Children: As the molecule's safety and efficacy has not been established in patients under 18 years of age, it cannot be recommended in this age group.Elderly patient: Lowest effective dose is recommended. The dosage can be raised to adult dosage if well tolerated.Hepatic impairment patient: Patients with mild to moderate liver function impairments must start with low amounts, and must closely be monitored. Artoflex 300 mg should not be used in patients with serious liver function impairment.Renal impairment patient: The starting amount must be reduced to patients with mild to moderate kidney function impairments. Artoflex 300 mg should not be used patients with serious kidney function impairments.

Drugs for Osteoarthritis, Drugs used for Rheumatoid Arthritis, Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Artoflex 300 mg (S (+)-ibuprofen) is considered as the pharmacologically active enantiomer of racemic ibuprofen. Like racemic ibuprofen, Artoflex 300 mg is a non-steroidal anti-inflammatory drug with analgesic action. Like ibuprofen, Artoflex 300 mg acts by inhibiting prostaglandin synthesis.Pharmacokinetics: Artoflex 300 mg is absorbed primarily from the small intestine. After metabolic transformation in the liver (hydroxylation, carboxylation) the pharmacologically inactive metabolites are completely excreted, mainly by the kidneys (90%), but also in the bile. The elimination half-life is 1.8-3.5 hours; the plasma protein binding is about 99%. Maximum plasma levels are reached about 2 hours after oral administration. The administration of Artoflex 300 mg with a meal delays the time to reach maximum concentrations (from 2.1 hours after fasting conditions to 2.8 hours after non-fasting conditions) and decreases the maximum plasma concentrations (from 20.6 to 18.1 mcg/ml, which is of no clinical relevance), but has no effect on the extent of absorption.

Pregnancy: Although no teratogennic impact has been observed in the animal-experimental research with Artoflex 300 mg or ibuprofen, the use should be avoided during the pregnancy. However, animal reproduction studies are not always predictive of human response. Because of the known effects of nonsteroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during late pregnancy should be avoided.Lactation: Studies at people have shown that racimic ibuprofen proceed in small to negligible degree in mother milk. So, Artoflex 300 mg should be used with cautions in nursing mothers.

Hepatic impairment: Patients with mild to moderate liver function impairments must start with low amounts, and must closely be monitored. Artoflex 300 mg should not be used in patients with serious liver function impairments.Renal impairment: The start amount must be reduced at patients with mild to moderate kidney function impairments. Artoflex 300 mg cannot be used patients with serious kidney function impairments.Children Dose: Although Artoflex 300 mg is not licensed for use in children under 18 years of age in the UK, some countries permit such use. For example, in Switzerland, Artoflex 300 mg has been given to children aged 6 years and over at a dose of 10 to 15 mg/kg daily in 2-4 divided doses.For elderly people: Lowest effective dose is recommended. The dosage can be raised to adult dosage if well tolerated.